A note from the Editor: At The Grand Investor, we keep an eye out for favorable circumstances we believe will interest our readers. The following is one such message from one of our colleagues I think you’ll appreciate.
Early investors in Amgen earned as much as 46,751% returns. And we believe early investors in this biotech have the potential to do the same. Their patented CRISPR technology has the potential to edit DNA - "cutting" the harmful genes and "pasting" the healthy ones. It's been called a "once-in-a-generation" opportunity. And as a dominant player, this firm controls the CRISPR patent other companies must license. Their market potential is enormous. Is this tiny company the next Amgen? "The Buck Stops Here," Dylan Jovine, CEO & Founder Behind the Markets
Got questions? We’ve got answers! Connect with our friendly support team to get the help you need, when you need it.
The Grand Investor is managed and possessed by Polaris Advertising. Polaris Advertising is the operator and proprietor of the The Grand Investor.
